Shares of 4DMedical Ltd (ASX:4DX) experienced a sharp decline on Friday, closing at A$3.20, a drop of 15.6%. The sell-off erased approximately A$354 million in market capitalization, based on the company's 599.64 million outstanding shares and the Friday exchange rate of US$0.6980 per Australian dollar.
The catalyst for the rout appears to be growing investor skepticism regarding a US legislative initiative. H.R. 9666, a bill that would authorize a five-year lung-imaging pilot program within the Department of Veterans Affairs (VA), remains stalled in committee. The bill proposes total funding of US$25 million, or roughly A$35.8 million at current exchange rates. The equity loss of A$354 million is nearly ten times the total proposed authorization, highlighting the market's sensitivity to this potential revenue stream.
4DMedical's CEO, Andreas Fouras, had hailed the initiative as a "landmark step" for veterans' respiratory care. However, the bill has not yet been enacted into law and is currently before the House Veterans’ Affairs Committee. Furthermore, it does not specify a vendor, leaving open the possibility that the VA could select a different qualified developer for the pilot program.
A key point of contention is the eligibility language in the legislation. The bill requires that any software used must be "approved" by the US Food and Drug Administration (FDA). 4DMedical's XV LVAS imaging software received 510(k) clearance from the FDA in May 2020, a premarket notification process that is distinct from the more rigorous premarket approval (PMA) pathway. The company asserts that XV LVAS meets the bill's definition, but the ambiguity in wording introduces procurement uncertainty.
Trading volume on Friday reached 13.7 million shares, nearly double the average volume reported on Google Finance. The broader S&P/ASX 200 index slipped only 0.5% on the same day, and shares of imaging software peer Pro Medicus Ltd (ASX:PME) fell 3.46%, suggesting that the selling pressure on 4DMedical was stock-specific rather than sector-wide.
Investors are now closely monitoring the progress of H.R. 9666 through the committee and any subsequent appropriations. The discrepancy between the US$20 million figure cited by 4DMedical in its ASX announcement and the US$25 million in the bill text adds to the confusion. The next concrete catalyst for the stock would be confirmation of a VA lease or contract, but for now, political and regulatory dynamics remain the dominant driver of share price movement.
